HA

Haemato AGHAM Haemato Stock Report

Last reporting period 30 Jun, 2023

Updated 08 Nov, 2024

Last price

Market cap $B

0.125

Micro

Exchange

XHAM - Hanseatische Wertpapierboerse Hamburg

HAEK.HM Stock Analysis

HA

Uncovered

Haemato AG is uncovered by Eyestock quantitative analysis.

Market cap $B

0.125

Dividend yield

Shares outstanding

5.21 B

Haemato AG engages in the pharmaceutical industry. The company is headquartered in Schoenefeld, Brandenburg and currently employs 150 full-time employees. The company went IPO on 2012-03-26. The firm trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The firm's main markets are Europe, North America and Japan. The company also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The firm's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.

View Section: Eyestock Rating